Literature DB >> 12831522

Comparison of chloroquine, albendazole and tinidazole in the treatment of children with giardiasis.

A A Escobedo1, F A Núñez, I Moreira, E Vega, A Pareja, P Almirall.   

Abstract

In a comparative trial, 165 Cuban children with confirmed giardiasis were randomized to receive albendazole (400 mg/day for 5 days), chloroquine (10 mg/kg twice daily for 5 days) or tinidazole (50 mg/kg, as a single dose). Parasitological follow-up was based on faecal samples collected 7 and 10 days after the completion of treatment. The tinidazole and chloroquine appeared equally effective (P > 0.05), curing 91% and 86% of the children treated, respectively, and significantly better (P < 0.01) than the albendazole, which only cured 62% of the children given it. All three drugs were well accepted and tolerated, with only mild, transient and self-limiting side-effects reported. Chloroquine appears to be a good alternative to tinidazole for the treatment of paediatric patients with giardiasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12831522     DOI: 10.1179/000349803235002290

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  10 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  Hospitalization of Cuban children for giardiasis: a retrospective study in a paediatric hospital in Havana.

Authors:  A A Escobedo; P Almirall; M Alfonso; Y Salazar; I Avila; S Cimerman; F A Núñez; I V Dawkins
Journal:  Ann Trop Med Parasitol       Date:  2011-01

3.  Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.

Authors:  Roberto Canete; Angel A Escobedo; Maria E Gonzalez; Pedro Almirall
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

4.  Treatment of giardiasis: current status and future directions.

Authors:  Richard R Watkins; Lars Eckmann
Journal:  Curr Infect Dis Rep       Date:  2014-02       Impact factor: 3.725

5.  Albendazole versus metronidazole treatment of adult giardiasis: An open randomized clinical study.

Authors:  Oguz Karabay; Ali Tamer; Huseyin Gunduz; Derya Kayas; Huseyin Arinc; Harika Celebi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

Review 6.  Efficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials.

Authors:  Vinay Pasupuleti; Angel Arturo Escobedo; Abhishek Deshpande; Priyaleela Thota; Yuani Roman; Adrian V Hernandez
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

7.  A novel in vitro image-based assay identifies new drug leads for giardiasis.

Authors:  Christopher J S Hart; Taylah Munro; Katherine T Andrews; John H Ryan; Andrew G Riches; Tina S Skinner-Adams
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-01-27       Impact factor: 4.077

Review 8.  Treatment-refractory giardiasis: challenges and solutions.

Authors:  Marco Lalle; Kurt Hanevik
Journal:  Infect Drug Resist       Date:  2018-10-24       Impact factor: 4.003

9.  The old and new therapeutic approaches to the treatment of giardiasis: where are we?

Authors:  Haendel G N O Busatti; Joseph F G Santos; Maria A Gomes
Journal:  Biologics       Date:  2009-07-13

Review 10.  Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia.

Authors:  Yukiko Miyamoto; Lars Eckmann
Journal:  Front Microbiol       Date:  2015-11-19       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.